Search Results - "Novisedlakova, Mária"

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients by Mego, Michal, Danis, Radoslav, Chovanec, Jozef, Jurisova, Silvia, Bystricky, Branislav, Porsok, Stefan, Konkolovsky, Peter, Vaclav, Vladimir, Wagnerova, Maria, Streško, Marian, Brezinova, Bibiana, Rečková, Mária, Sutekova, Dagmar, Pazderova, Natalia, Novisedlakova, Mária, Zomborska, Eva, Ciernikova, Sona, Svetlovska, Daniela, Drgona, Lubos

“…BackgroundThe incidence of irinotecan-induced diarrhea varies between 60-90%, by which the incidence of severe diarrhea is 20-40%. The objective of this phase…”
Get full text

DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines by Urbanova, Maria, Buocikova, Verona, Trnkova, Lenka, Strapcova, Sabina, Kajabova, Viera Horvathova, Melian, Emma Barreto, Novisedlakova, Maria, Tomas, Miroslav, Dubovan, Peter, Earl, Julie, Bizik, Jozef, Svastova, Eliska, Ciernikova, Sona, Smolkova, Bozena

“…Due to abundant stroma and extracellular matrix, accompanied by lack of vascularization, pancreatic ductal adenocarcinoma (PDAC) is characterized by severe…”
Get full text

The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma by Ciernikova, Sona, Novisedlakova, Maria, Cholujova, Danka, Stevurkova, Viola, Mego, Michal

“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors due to the absence of biomarkers for early-stage detection and poor…”
Get full text

Prognostic and predictive significance of inflammatory markers in patients with locally advanced unresectable and metastatic pancreatic cancer treated with first-line chemotherapy FOLFIRINOX or Gemcitabine/Nabpaclitaxel by Novisedlakova, Maria, Chovanec, Michal, Ciernikova, Sona, Danihel, Ludovit

“…Advanced pancreatic ductal adenocarcinoma (PDAC) remains a disease with a dismal prognosis, significantly limited therapeutic options, and few innovative…”
Get full text

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium , BB-12 and Lactobacillus rhamnosus , LGG in colorectal cancer patients: The Probio SK 006-Slovak cooperative oncology group trial by Mego, Michal, Danis, Radoslav, Chovanec, Jozef, Jurisova, Silvia, Bystricky, Branislav, Porsok, Stefan, Konkolovsky, Peter, Vaclav, Vladimir, Wagnerova, Maria, Stresko, Marian, Brezinova, Bibiana, Reckova, Maria, Sutekova, Dagmar, Pazderova, Natalia, Novisedlakova, Maria, Zomborska, Eva, Ciernikova, Sona, Svetlovska, Daniela, Drgona, Lubos

“…e24109 Background: The incidence of irinotecan-induced diarrhea varies between 60-90%, by which the incidence of severe diarrhea is 20-40%. The objective of…”
Get full text

New trends in criteria indicative of neoadjuvant oncological therapy of lower and middle rectal cancers by Kukucka, Martin, Danihel, Ludovit, Oravsky, Milan, Rajcok, Matus, Bernadic, Michal, Kovarova, Paula, Cerny, Natalie Birknerova Marian, Novisedlakova, Maria, Drahokoupilova, Miriam, Schnorrer, Milan

“…The indication for primary surgical resection or neoadjuvant therapy in lower and middle rectal cancers is often disputable. The aim of the study was to…”
Get full text